CALB2 and Miyoshi myopathy: Around 1995, antibodies against Wilms tumour protein (WT) 1, around 1998, against Calretinin and around 2005, against Podoplanin/D2-40 were introduced into routine diagnostics as new positive MM markers [16-22].